FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309661341> ?p ?o ?g. }

• W4309661341 abstract "This is the third update of the review first published in 2017. Hypertension is a prominent preventable cause of premature morbidity and mortality. People with hypertension and established cardiovascular disease are at particularly high risk, so reducing blood pressure to below standard targets may be beneficial. This strategy could reduce cardiovascular mortality and morbidity but could also increase adverse events. The optimal blood pressure target in people with hypertension and established cardiovascular disease remains unknown.To determine if lower blood pressure targets (systolic/diastolic 135/85 mmHg or less) are associated with reduction in mortality and morbidity compared with standard blood pressure targets (140 mmHg to 160mmHg/90 mmHg to 100 mmHg or less) in the treatment of people with hypertension and a history of cardiovascular disease (myocardial infarction, angina, stroke, peripheral vascular occlusive disease).For this updated review, we used standard, extensive Cochrane search methods. The latest search date was January 2022. We applied no language restrictions.We included randomized controlled trials (RCTs) with more than 50 participants per group that provided at least six months' follow-up. Trial reports had to present data for at least one primary outcome (total mortality, serious adverse events, total cardiovascular events, cardiovascular mortality). Eligible interventions involved lower targets for systolic/diastolic blood pressure (135/85 mmHg or less) compared with standard targets for blood pressure (140 mmHg to 160 mmHg/90 mmHg to 100 mmHg or less). Participants were adults with documented hypertension and adults receiving treatment for hypertension with a cardiovascular history for myocardial infarction, stroke, chronic peripheral vascular occlusive disease, or angina pectoris.We used standard Cochrane methods. We used GRADE to assess the certainty of the evidence.We included seven RCTs that involved 9595 participants. Mean follow-up was 3.7 years (range 1.0 to 4.7 years). Six of seven RCTs provided individual participant data. None of the included studies was blinded to participants or clinicians because of the need to titrate antihypertensive drugs to reach a specific blood pressure goal. However, an independent committee blinded to group allocation assessed clinical events in all trials. Hence, we assessed all trials at high risk of performance bias and low risk of detection bias. We also considered other issues, such as early termination of studies and subgroups of participants not predefined, to downgrade the certainty of the evidence. We found there is probably little to no difference in total mortality (risk ratio (RR) 1.05, 95% confidence interval (CI) 0.91 to 1.23; 7 studies, 9595 participants; moderate-certainty evidence) or cardiovascular mortality (RR 1.03, 95% CI 0.82 to 1.29; 6 studies, 9484 participants; moderate-certainty evidence). Similarly, we found there may be little to no differences in serious adverse events (RR 1.01, 95% CI 0.94 to 1.08; 7 studies, 9595 participants; low-certainty evidence) or total cardiovascular events (including myocardial infarction, stroke, sudden death, hospitalization, or death from congestive heart failure (CHF)) (RR 0.89, 95% CI 0.80 to 1.00; 7 studies, 9595 participants; low-certainty evidence). The evidence was very uncertain about withdrawals due to adverse effects. However, studies suggest more participants may withdraw due to adverse effects in the lower target group (RR 8.16, 95% CI 2.06 to 32.28; 3 studies, 801 participants; very low-certainty evidence). Systolic and diastolic blood pressure readings were lower in the lower target group (systolic: mean difference (MD) -8.77 mmHg, 95% CI -12.82 to -4.73; 7 studies, 8657 participants; diastolic: MD -4.50 mmHg, 95% CI -6.35 to -2.65; 6 studies, 8546 participants). More drugs were needed in the lower target group (MD 0.56, 95% CI 0.16 to 0.96; 5 studies, 7910 participants), but blood pressure targets at one year were achieved more frequently in the standard target group (RR 1.20, 95% CI 1.17 to 1.23; 7 studies, 8699 participants).We found there is probably little to no difference in total mortality and cardiovascular mortality between people with hypertension and cardiovascular disease treated to a lower compared to a standard blood pressure target. There may also be little to no difference in serious adverse events or total cardiovascular events. This suggests that no net health benefit is derived from a lower systolic blood pressure target. We found very limited evidence on withdrawals due to adverse effects, which led to high uncertainty. At present, evidence is insufficient to justify lower blood pressure targets (135/85 mmHg or less) in people with hypertension and established cardiovascular disease. Several trials are still ongoing, which may provide an important input to this topic in the near future." @default.
• W4309661341 created "2022-11-29" @default.
• W4309661341 creator A5004419394 @default.
• W4309661341 creator A5010307101 @default.
• W4309661341 creator A5013056953 @default.
• W4309661341 creator A5029690041 @default.
• W4309661341 creator A5067000131 @default.
• W4309661341 creator A5071254204 @default.
• W4309661341 date "2022-11-18" @default.
• W4309661341 modified "2023-09-23" @default.
• W4309661341 title "Blood pressure targets for the treatment of people with hypertension and cardiovascular disease" @default.
• W4309661341 cites W1480729244 @default.
• W4309661341 cites W1709919176 @default.
• W4309661341 cites W1908289777 @default.
• W4309661341 cites W1924841915 @default.
• W4309661341 cites W1948745084 @default.
• W4309661341 cites W1966479854 @default.
• W4309661341 cites W1970475964 @default.
• W4309661341 cites W1970629917 @default.
• W4309661341 cites W1987864685 @default.
• W4309661341 cites W1988716175 @default.
• W4309661341 cites W1990908213 @default.
• W4309661341 cites W2000009266 @default.
• W4309661341 cites W2004122631 @default.
• W4309661341 cites W2006918689 @default.
• W4309661341 cites W2009917149 @default.
• W4309661341 cites W2021334280 @default.
• W4309661341 cites W2021988356 @default.
• W4309661341 cites W2023144631 @default.
• W4309661341 cites W2023872059 @default.
• W4309661341 cites W2025545342 @default.
• W4309661341 cites W2034036386 @default.
• W4309661341 cites W2059647022 @default.
• W4309661341 cites W2068171275 @default.
• W4309661341 cites W2075082363 @default.
• W4309661341 cites W2076316624 @default.
• W4309661341 cites W2079663279 @default.
• W4309661341 cites W2085989892 @default.
• W4309661341 cites W2086345133 @default.
• W4309661341 cites W2087153968 @default.
• W4309661341 cites W2092075924 @default.
• W4309661341 cites W2102194155 @default.
• W4309661341 cites W2102312517 @default.
• W4309661341 cites W2103202569 @default.
• W4309661341 cites W2108790161 @default.
• W4309661341 cites W2116363103 @default.
• W4309661341 cites W2118341353 @default.
• W4309661341 cites W2119543188 @default.
• W4309661341 cites W2120235169 @default.
• W4309661341 cites W2121267642 @default.
• W4309661341 cites W2124239768 @default.
• W4309661341 cites W2124247204 @default.
• W4309661341 cites W2126125759 @default.
• W4309661341 cites W2126805804 @default.
• W4309661341 cites W2127422554 @default.
• W4309661341 cites W2129336294 @default.
• W4309661341 cites W2133082762 @default.
• W4309661341 cites W2133416234 @default.
• W4309661341 cites W2135193555 @default.
• W4309661341 cites W2136145230 @default.
• W4309661341 cites W2137408480 @default.
• W4309661341 cites W2137978158 @default.
• W4309661341 cites W2142742490 @default.
• W4309661341 cites W2149505436 @default.
• W4309661341 cites W2156121263 @default.
• W4309661341 cites W2164547687 @default.
• W4309661341 cites W2167142042 @default.
• W4309661341 cites W2198866495 @default.
• W4309661341 cites W2205577567 @default.
• W4309661341 cites W2286350689 @default.
• W4309661341 cites W2303651371 @default.
• W4309661341 cites W2312999996 @default.
• W4309661341 cites W2321986725 @default.
• W4309661341 cites W2332227009 @default.
• W4309661341 cites W2342178794 @default.
• W4309661341 cites W2394553765 @default.
• W4309661341 cites W2402203869 @default.
• W4309661341 cites W2402599050 @default.
• W4309661341 cites W2437822687 @default.
• W4309661341 cites W2475261460 @default.
• W4309661341 cites W2483196217 @default.
• W4309661341 cites W2512086803 @default.
• W4309661341 cites W2579221121 @default.
• W4309661341 cites W2626357523 @default.
• W4309661341 cites W2768267412 @default.
• W4309661341 cites W2792254568 @default.
• W4309661341 cites W2805891433 @default.
• W4309661341 cites W2885907396 @default.
• W4309661341 cites W2888589263 @default.
• W4309661341 cites W2891763507 @default.
• W4309661341 cites W2899736836 @default.
• W4309661341 cites W2899773405 @default.
• W4309661341 cites W2909018136 @default.
• W4309661341 cites W2964879579 @default.
• W4309661341 cites W2980283866 @default.
• W4309661341 cites W3021842026 @default.
• W4309661341 cites W3023969949 @default.
• W4309661341 cites W3034899365 @default.
• W4309661341 cites W3092311802 @default.
• W4309661341 cites W3092500625 @default.

• next